ARQT · XBRL financial data

Arcutis Biotherapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ARQT's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue	14*	50	31	45	71*	66	82	99	130*	105	130	144
Cost of goods and services sold	2*	3	3	6	7*	9	7	9	12*	10	11	12
Research and development	24*	23	19	20	14*	18	19	20	20*	31	20	22
Selling, general and administrative	49*	55	58	59	58*	64	69	62	79*	74	82	100
Operating income (loss)	(61)*	(32)	(50)	(39)	(8)*	(25)	(15)	9	18*	(9)	16	9
Interest income	—	—	—	—	—	—	2	2	—	—	2	3
Interest expense	8*	7	7	7	6*	3	3	3	3*	4	3	3
Other income (expense)	3*	4	5	4	3*	3	2	2	(6)*	(0)	(0)	(0)
Income tax expense (benefit)	0*	0	0	0	0*	0	0	0	0*	0	0	0
Net income (loss)	(66)*	(35)	(52)	(42)	(11)*	(25)	(16)	7	17*	(11)	15	9
Earnings per share, basic USD per share	—	(0.32)	(0.42)	(0.33)	(0.09)*	(0.20)	(0.13)	0.06	0.14*	(0.09)	0.11	0.07
Earnings per share, diluted USD per share	—	(0.32)	(0.42)	(0.33)	(0.09)*	(0.20)	(0.13)	0.06	0.14*	(0.09)	0.11	0.06
Weighted average shares, basic millions of shares	—	111	123	124	125*	126	127	128	128*	0	131	131
Weighted average shares, diluted millions of shares	—	111	123	124	125*	126	127	133	123*	0	136	137

Fiscal quarters (ARQT's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	88	190	84	135	71	53	73	47	43	35	34	33
Marketable securities	183	214	278	196	157	145	118	144	178	189	204	226
Accounts receivable	26	37	43	60	73	85	107	115	146	144	155	171
Inventory	13	13	14	14	15	17	16	22	23	37	39	46
Prepaid and other current assets	19	13	14	18	20	23	19	20	21	32	35	27
Total current assets	330	468	435	424	336	324	333	349	411	438	468	504
Property and equipment, net	2	1	1	1	1	1	1	1	1	1	1	1
Right-of-use asset	2	2	2	2	2	2	2	5	4	4	4	4
Total assets	341	479	445	437	349	344	352	371	433	460	489	524
Accounts payable	12	13	8	19	14	25	15	6	13	18	7	8
Accrued liabilities	34	34	43	53	66	66	88	93	116	137	147	157
Current portion of long-term debt	0	—	—	100	0	—	1	1	1	8	7	7
Total current liabilities	47	47	51	172	81	91	104	100	130	163	160	172
Long-term debt	202	203	204	105	107	108	107	107	108	101	102	102
Lease liability, non-current	3	3	3	3	3	2	2	5	5	5	5	5
Total liabilities	253	254	258	281	191	201	213	213	243	270	268	280
Accumulated deficit	(982)	(1,017)	(1,070)	(1,111)	(1,122)	(1,147)	(1,163)	(1,155)	(1,138)	(1,149)	(1,134)	(1,126)
Total stockholders' equity	89	225	186	157	158	143	139	158	189	190	221	244
Total liabilities and equity	341	479	445	437	349	344	352	371	433	460	489	524
Common shares outstanding (cover page) millions of shares	97	116	117	117	119	119	120	122	124	125	126	126

Fiscal quarters (ARQT's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(66)*	(35)	(52)	(42)	(11)*	(25)	(16)	7	17*	(11)	15	9
Stock-based compensation	9*	10	13*	10*	9*	10	10*	10*	10*	11	13*	12*
Net cash from operating activities	(56)*	(32)	(45)*	(35)*	(1)*	(30)	0*	(2)*	26*	2	13*	19*
Purchases of property and equipment	0*	0	0*	0*	0*	1	0*	0*	0*	0	0*	0*
Net cash from investing activities	(62)*	(29)	(62)*	85*	35*	12	17*	(25)*	(34)*	(11)	(15)*	(22)*
Proceeds from issuing common stock	0*	162	0*	0*	0*	0	0*	0*	0*	—	—	—
Proceeds from long-term debt	0*	—	—	—	year only	—	—	—	—	—	—	—
Repayments of long-term debt	year only	—	—	—	year only	—	—	—	year only	—	—	—
Net cash from financing activities	99*	162	1*	0*	(97)*	0	1*	1*	4*	1	2*	2*
Net change in cash	(19)*	101	(106)*	51*	(64)*	(18)	19*	(26)*	(4)*	(8)	(1)*	(1)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Arcutis Biotherapeutics	33	144	19*	126.5M	—	Q3 FY26 10-QSep 30, 2026
Ligand Pharmaceuticals	56	79	(28)*	20.0M	—	Q3 FY26 10-QSep 30, 2026
Ocular Therapeutix	599	13	(67)*	219.6M	8.9 quarters	Q2 FY26 10-QJun 30, 2026
Arrowhead Pharmaceuticals	55	75	(177)*	141.3M	9.0 quarters	Q3 FY26 10-QJun 30, 2026
Sarepta Therapeutics	571	401	197*	105.6M	—	Q2 FY26 10-QJun 30, 2026
Adaptive Biotechnologies	76	84	9.6*	161.9M	—	Q3 FY26 10-QSep 30, 2026
Supernus Pharmaceuticals	176	227	6.6*	58.2M	—	Q3 FY26 10-QSep 30, 2026
Amicus Therapeutics	214	185*	16*	314.0M	—	Q4 FY25 10-KDec 31, 2025
Travere Therapeutics	124	225	98*	96.0M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.